T1D is a managed disease in need of a cure and despite the investment made in novel insulin formulations and glycemia level-activated pumps, pharmacologic insulin replacement fails to achieve a return to stable and long-term physiologic glycemic variability, to avoid the onset of the complications (2–7). This evidence concerns the gene INS and type 1 diabetes mellitus.